Providers

Recent advances have marked a turning point for the treatment noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), with more therapies on the horizon to hopefully better address patients' cirrhosis, explained Naim Alkhouri, MD.

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

As drug denials increase, experts discuss the importance of optimizing data to keep up with these changes and implementing artificial intelligence (AI) to reduce the burden on providers and ensure patient access to care and treatment.

Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.

Elizabeth Grush, MBA, speaks to the support, benefits, and holistic considerations that patient-centered care can provide for the betterment of patient experiences and outcomes.

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

While findings around hospital and emergency department use were similar at the individual and neighborhood levels, the use of outpatient services differed.

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like peptide 1 (GLP-1) receptor agonists for liver conditions.

The immunotherapy improved outcomes compared with standard chemotherapy in the global Phase 3 DeLLphi-304 trial.

Findings from the interviews offer insight into potential strategies for reducing binge eating among patients who experience food insecurity.

Data from a meta-analysis of 8 observational studies accounting for more than 26 million people across the globe were evaluated in a new review.

None of the eteplirsen-treated patients reached a left ventricular ejection fraction below 50% compared with 22.1% of patients in the control group.

This study found no evidence that hospital employment of physicians resulted in physicians treating sicker patients, undercutting claims that hospital-employed physicians serve a higher-acuity patient mix.

Investigators highlighted Raman spectroscopy, a noninvasive diagnostic technology that could lead to faster, earlier detection of skin cancer.

Joseph Saseen, PharmD, discussed the importance of knowing lipoprotein a (Lp[a]) levels to enable clinicians to provide the best patient care and spread awareness to those who might be affected.

This article appears in the April issue of Evidence-Based Oncology.

Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

A higher percentage of accountable care organization (ACO) primary care providers was associated with physician leadership, upside financial risk, and financial compensation of physicians tied to performance measures.

A coverage with evidence development (CED) study demonstrated significant and clinically meaningful benefits in patients with migraine treated with remote electrical neuromodulation (REN). Health plans should support clinicians’ REN prescriptions by ensuring adequate coverage.

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.

Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual Scientific Session.

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses findings from the phase 3 Precision-T trial of Orca-T in acute leukemia and myelodysplastic syndrome (MDS).

Mobile self-management programs like that offered by Hello Heart can benefit employers and patients alike as they seek to manage and prevent heart disease.